Biogen stock slides 1.77 percent as Biogen announces kidney data presentations in Europe and US

Traders Union
All News
Business & Wealth
Companies
Biogen drops 1.77% to $188.83 today

Highlights

BIIB remains under short-term selling pressure, but its medium- and long-term uptrend is technically intact despite a recent 3.66% decline.
Oscillators show the stock in oversold territory with a weak trend, signaling potential for a rebound within the current range.
BIIB is expected to trade between $188.00 and $195.00 next week, with major support at $187.00 and resistance at $192.50.

Biogen said information on its kidney research will be available through conference presentations. The announcement included a link for further details.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Short-term downside persists as price tests resistance above key supports

BIIB is trading at $188.83, which is below the MA-20 ($193.39) but slightly above the MA-50 ($187.05) and well above the MA-200 ($171.11). This setup signals short-term downside pressure, but medium- and long-term bullish structure remains intact. The Ichimoku Kijun at $192.56 is above the current price, marking immediate resistance. Near-term support is at the MA-50 ($187.05) with key support at the MA-100 ($185.68). Immediate resistance lies at the Kijun ($192.56), with key resistance at the MA-20 ($193.39).

Bearish momentum intensifies as oversold conditions drive weekly declines

Momentum on D1 is mixed, with MACD signaling strong buy but ADX showing weak, neutral trend strength. Oscillators indicate oversold conditions as seen in Stoch RSI (0.00) and CCI (-111.86), while RSI (46.84) is in neutral bearish territory. BBP is deeply negative (-2.37), confirming sellers are currently dominant. BIIB has fallen $7.17 (3.66%) from last week's close of $196.00, positioning the price in the lower part of the weekly range. Weekly volatility stands at 8.12%. The decline is steady, with sellers controlling the tone. In today's session, the stock is down 1.77%, signaling continued intraday pressure.

Bullish bias prevails as weekly trend signals anchor price range high

For the next week, BIIB is expected to trade between $188.00 and $195.00, a range close to the current level and in line with recent volatility. The probability of a price increase is high (more than 80%) given that all key W1 trend indicators—RSI, MACD, ADX, and MA-50—signal "Buy" or "Strong Buy". The probability of a decline is thus very low. Baseline scenario: BIIB holds within a sideways band, stabilizing between support and resistance. Bullish scenario: a close above $192.50 could trigger a move toward $195.00. Bearish scenario: a drop below $187.00 could open a test near $185.70. The forecast range remains well above the 52-week low ($121.05), but slightly below the 52-week high ($205.97), anchoring BIIB in the upper third of its yearly band.

Previously it was reported that Biogen faced near-term bearish momentum but maintained a constructive long-term technical outlook. As the situation has evolved, investors should now focus on the latest price action for signs of a sustained trend reversal or confirmation of ongoing consolidation.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.